Search CADL
Candel Therapeutics, Inc.
Nasdaq · CIK 1841387
Last close10.18
Daily change+0.02 (0.20%)
10 Years gain+45.43%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CADL · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
26.3Momentum
0.0Acceleration
0.0Confidence
61.0Annual Revenue3
Quarterly Revenue10
Annual CFO6
Balance SheetMissing
RankingLimited
Score Breakdown
Growth0.0 / 25
Quality6.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.1 / 15
Shareholder Economics5.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
Operating margin compression · MEDIUMOperating margin compressed by 7196.8 percentage points.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM0%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-27,777.6%OK
FCF Margin-26,172.8%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0xOK
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenue1,845.6%OK
SBC / FCF-7.05%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$48.27M | -$38.31M | -$38.90M | n/a | n/a | n/a | n/a | 52.96M |
| 2025 FY Dec 31, 2024 | n/a | $0.00 | -$33.37M | -$27.02M | -$27.04M | n/a | n/a | n/a | n/a | 31.68M |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$38.39M | -$34.24M | -$34.70M | n/a | n/a | n/a | n/a | 28.94M |
| 2023 FY Dec 31, 2022 | $125,000.00 | $125,000.00 | -$34.72M | -$31.42M | -$32.72M | 100% | -27,777.6% | -26,172.8% | n/a | 28.82M |
| 2022 FY Dec 31, 2021 | $125,000.00 | $125,000.00 | -$25.73M | -$22.22M | -$24.05M | 100% | -20,580.8% | -19,242.4% | n/a | 18.87M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $125,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0000950170-23-020873, 0000950170-23-040984 |
| Revenue Growth TTM | 0% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000950170-23-020873, 0000950170-23-040984 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0000950170-24-037637 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0000950170-24-037637 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0000950170-24-037637 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-23-020873, 0000950170-23-040984 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-23-020873, 0000950170-23-040984 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0000950170-23-020873, 0000950170-23-040984 |
| Operating Margin | -27,777.6% | Operating Income / Revenue | OK | 0000950170-23-020873, 0000950170-23-040984 |
| FCF Margin | -26,172.8% | (CFO - CapEx) / Revenue | OK | 0000950170-23-020873, 0000950170-23-040984 |
| Net Debt / CFO | 0x | Net Debt / CFO | OK | 0000950170-23-020873, 0000950170-23-040984 |
| SBC / Revenue | 1,845.6% | SBC / Revenue | OK | 0000950170-23-020873, 0000950170-23-040984 |
| SBC / FCF | -7.05% | SBC / FCF | OK | 0000950170-23-020873, 0000950170-23-040984 |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0000950170-24-037637 |